In vivo antidiabetic drug discovery

Bibliography

• KUBINYI H: Strategies and recent technologies in drug discovery. Phamazie (1995) 50:647–662.
   PubMed Web of Science ®Google Scholar
• •Comprehensive review on drug discovery strategies and new technologies BRUGGE JS: New intracellular targets for therapeutic drug design. Science (1993) 260:918-919. MACFARLANE IA: The millennia before insulin. In : Text-book of Diabetes. Pickup J, Williams G (Ed.), Blackwell Sci-entific Publications, London, UK (1990:3–9.
   Google Scholar
• BLISS M: The discovery of insulin. In: Textbook of Diabe- tes. Pickup J, Williams G (Eds.), Blackwell Scientific Publica-tions, London, UK (1990:10–14.
   Google Scholar
• JANBON M, CHAPTAL J, VEDEL A, SCHAAP J: Accidents hypoglycemiques graves par un sulfamidothiazol (le Vkou 2254 RP). Montpellier Med. (1942):21–22,441-444.
   Google Scholar
• LOUBATIERES AL: The hypoglycemic sulphonamides: history and development of the problem from 1942 to 1955. Ann. NY Acad. Sci. (1955) 80:1449.
   Google Scholar
• SMONNET HG, TANRET G: Sur les proprietes hypogly-cemiantes du sulfate de gelegine. Bull. Soc. Chim. Biol. (1927) 9:908–927.
   Google Scholar
• WAANABE CK: Studies in the metabolic changes in-duced by administration of guanidine bases. J. Biol. Chem. (1918) 33:253–65.
   Google Scholar
• PERL M: The biochemical basis of the hypoglycemic ef-fects of some plant extracts. In: Herbs, Spices and Medici-nal Plants: Recent Advances in Botany, Horticulture, and Pharmacology (vol. 3). Craker LE, Simon JE (Eds.), Oryx Press; Phoenix, USA (1988):49–70.
   Google Scholar
• KOBAYASHI M: Effects of thiazolidinediones in diabe-tes mellitus. Symposium Of Thiazolidinediones In The Treatment Of Insulin Resistance And NIDDM: Current Stat-ues And Future Role. San Francisco, California, USA (1996), .
   Google Scholar
• MAXWELL RA: The state of the art of the science of drugdiscovery-an opinion. Drug Dev. Res. (1984) 4:375–389.
   Web of Science ®Google Scholar
• •Interesting discussion on approaches to drug discovery
   Google Scholar
• DUHAULT J, LAVIELLE R: History and evolution of the concept of oral therapy in diabetes. Diab. Res. Clin. Prac. (1991) 14:S9–S14.
   Web of Science ®Google Scholar
• BOGARDUS C: Metabolic abnormalities in the develop-ment of non-insulin- dependent diabetes mellitus. In: Diabetes Mellitus: A Fundamental And Clinical Text. Le-Roith D, Tayler SI, Olefsky JM (Eds.), Lippincott-Raven Pub-lishers, Philadelphia, PA, USA (1996):459–467.
   Google Scholar
• SCHEEN AJ: Drug treatment of non-insulin-dependent diabetes mellitus in the 1990s. Drugs (1997) 54:355–368.
   PubMed Web of Science ®Google Scholar
• DUNN CJ, PETERS DH: Metformin. A review of its phar-macological properties and therapeutic use in non-insulin-dependent diabetes mellitus. Drugs (1995) 49:721–749.
   Google Scholar
• SALTIEL AR, OLEFSKY JM: Thiazolidinediones in thetreatment of insulin resistance and type II diabetes. Diabetes (1996) 45(12):1661–1669.
   PubMed Web of Science ®Google Scholar
• IMURA H: A novel antidiabetic drug, troglitazone- reason for hope and concern. New Engl. J. Med. (1998) 338:908–909.
   PubMed Web of Science ®Google Scholar
• SPIEGELMAN BM: PPAR-y: adipogenic regulator and thiazolidinedione receptor. Diabetes (1998) 47(4)507–514.
   Google Scholar
• •Comprehensive review on PPAR-1, and its therapeutic potential
   Google Scholar
• IRWIN S: Drug screening and evaluative procedures. Science (1962) 136:123–128.
   PubMed Web of Science ®Google Scholar
• •Emphasises the importance of use of intact animals
   Google Scholar
• KETY SS: A biologist examines the mind and behavior. Science (1960) 132:1861–1870
   PubMed Web of Science ®Google Scholar
• GOLDIN SM: Drug discovery technology: evolution and revolution. Drug Market Dev. (1997) 8(12) :280–286.
   Google Scholar
• GOLDIN SM: Drug discovery technology: a marriage of disciplines. Drug Market Dev. (1997) 8(3) :66–71.
   Google Scholar
• LEHMANN JM, MOORE LB, SMITH-OLIVER TA et al: An an-tidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator-activated receptor gamma (PPAR gamma). J. Biol. Chem. (1995) 270:12953–12956.
   PubMed Web of Science ®Google Scholar
• LIPWORTH BJ: Clinical pharmacology of 0-adrenoce-ptors. Br. J. Clin. Pharmacol. (1996) 42:291–300.
   PubMed Web of Science ®Google Scholar
• BISBEE CA: Genomic approach to drug discovery target identification. Drug Market Dev. (1997) 8(6) :140–143.
   Google Scholar
• Kahn CR: Banting Lecture. Insulin action, diabe-togenes, and the cause of type II diabetes. Diabetes (1994) 43 (8) :1066–1084.
   Google Scholar
• •Comprehensive review on the pathophysiology of type 2 diabetes
   Google Scholar
• REAVEN GM: Role of insulin resistance in human dis-ease. Diabetes (1988) 37:1595–1607.
   PubMed Web of Science ®Google Scholar
• PORTE D, Jr.: Banting Lecture 1990. Beta-cells in type II diabetes mellitus. Diabetes (1991) 40:166–180.
   Google Scholar
• ERIKSSON J, FRANSSILA-KALLUNKI A, EKSTRAND A et al: early metabolic defects in persons at increased risk for non-insulin-dependent diabetes mellitus. New Engl. J. Med. (1989) 321:337–343.
   PubMed Web of Science ®Google Scholar
• LAWS A, STEFANICK ML, REAVEN GM: Insulin resistance andhypertriglyceridemia in nondiabetic relatives ofpatients with non-insulin-dependent diabetes melli-tus. J. Clin. Endocrinol Metab. (1989) 69:343–347.
   PubMed Web of Science ®Google Scholar
• HO LT, CHANG ZY, WANG JT et al.: Insulin insensitivity in offspring of parents with type 2 diabetes mellitus. Diabetic Med. (1990) 7:31–34.
   PubMed Web of Science ®Google Scholar
• CHEATHAN B, KAHN CR: The biochemistry of insulin action. In: Diabetes Mellitus: A Fundamental And Clinical Text. LeRoith D, Tayler SI, Olefsky JM (Eds.), Lippincott-Raven Publishers, Philadelphia, PA, USA (1996):139–147.
   Google Scholar
• •Comprehensive review on normal insulin action at the mo-lecular level
   Google Scholar
• CARO JF, SHAFER JA, TAYLOR SI et al: Insulin stimulated protein phosphorylation in human plasma liver mem-branes: detection of endogenous or plasma membrane associated substrates for insulin receptor kinase. Bio- chem. Biophys. Res. Commun. (1987) 149:1008–1016.
   PubMed Web of Science ®Google Scholar
• GOODYEAR LJ, GIORGINO F, SHERMAN LA et al: Insulin receptor phosphorylation, IRS-1 phosphorylation, and phosphatidylinositol 3- kinase activity are de-creased in intact skeletal muscle strips from obese sub-jects. J. Clin. Invest. (1995) 95 (5) :2195–2204.
   PubMed Web of Science ®Google Scholar
• CARO JF, RAJU MS, CARO M et al.: Guanine nucleotide binding regulatory protein in liver from obese hu-mans with and without type II diabetes: evidence for altered 'cross-talk' between the insulin receptor and Gi-protein. J. Cell. Biochem. (1994) 54:309–319.
   PubMed Web of Science ®Google Scholar
• PROIETTO J, ANDRIKOPOULOS S, ROSELLA G, THOR-BURN A: Understanding the pathogenesis of type 2 dia-betes: can we get off the metabolic merry-go-rounds? Aust. NZ J. Med. (1995) 25(6):870–875.
   Google Scholar
• ARCH JR, WILSON S: Prospects for 0-3 adrenoceptor agonists in the treatment of obesity and diabetes. Int. J. Obes. Relat. Metab. Disord. (1996) 20:191–199.
   PubMed Web of Science ®Google Scholar
• RATHEISER K, SCHNEEWEISS B, WALDH AUSL W et al: In-hibition by etomoxir of carnitine palmitoyltransfe-rase I reduces hepatic glucose production and plasma lipids in non-insulin-dependent diabetes mellitus. Me-tabolism (1991) 40:1185–1190.
   PubMed Web of Science ®Google Scholar
• JONES RB, DICKINSON K, ANTHONY DM et al.: Evalua-tion of BTS 67582, a novel antidiabetic agent, in nor-mal and diabetic rats. Br. J. Pharmacol. (1997) 120:1135–1143.
   PubMed Web of Science ®Google Scholar
• OUBR AY CARLSON TJ, KING SR, REAVEN GM: From plant to patient: an ethnomedical approach to the identification of new drugs for the treatment of NIDDM. Diabetologia (1997) 40:614–617.
   PubMed Web of Science ®Google Scholar
• ••Concept of Shaman antidiabetic drug discovery programme.
   Google Scholar
• LUO J, FORT DM, CARLSON TJ et al: Cryptolepis sangui- nolenta: an ethnobotanical approach to drug discov-ery and the isolation of a potentially useful new antihyperglycaemic agent. Diabetic Med. (1998) 15:367–374.
   PubMed Web of Science ®Google Scholar
• ••First active compound isolated by Shaman's in vivo drug dis-covery approach.
   Google Scholar
• SHAFRIR E: Animal models of non-insulin-dependentdiabetes. Diabetes Metab. Rev. (1992) 8(3):179–208.
   PubMed Web of Science ®Google Scholar
• REAVEN GM, CHEN Y-DI, HOLLENBECK CB et al: Plasmainsulin, C-peptide, and proinsulin concentrations in obese and nonobese individuals with varying degrees of glucose tolerance. J. Clin. Endocrinol Metab. (1993) 76:44–48.
   PubMed Web of Science ®Google Scholar
• LUO J, QUAN J, TSAI J et al: Non-genetic mouse models of non-insulin-dependent diabetes mellitus. Metabo-lism (1998) 47(6):1–7.
   Google Scholar
• LUO J, CHUANG T, CHEUNG J: Masoprocol: a new anti-hyperglycemic agent isolated from the creosote bush (Larrea tridentata). Eur.j Phamacol. (1998) (In Press.)
   Google Scholar
• THE WORLD HEALTH REPORT 1997: Conquering suffer-ing, enriching humanity. World Health Organization Publication (1998).v © Ashley Publications Ltd. All rights reserved.Exp. Opin. Invest. Drugs (1998) 7(6)
   Google Scholar
• GEISS LS, HERMAN WH, GOLDSCHMID MG et al.: Surveil-lance for diabetes mellitus—United States' 1980-1989. MMWR CDC Surveil]. Summ. (1993) 42:1–20.
   PubMedGoogle Scholar
• LEIBOWITZ G, CERASI E: Sulphonylurea treatment of NIDDM patients with cardiovascular disease: a mixed blessing? Diabetologia (1996) 39 (5):503–514.
   PubMed Web of Science ®Google Scholar
• SULKIN TV, BOSMAN D, KRENTZ AJ: Contradictions to metformin therapy in patients with NIDDM. Diabetes Care (1997) 20(6):925–928.
   PubMed Web of Science ®Google Scholar
• HOLLANDER P: Safety profile of acarbose, an alpha-glucosidase inhibitor. Drugs (1992) 44\(Suppl. 3)47–53.
   Google Scholar
• In: Hepatic dysfunction associated with troglitazone. Watkins PB, Whitcomb RW (Eds.). New Engl. J. Med. (1998) 338:916–917.
   Google Scholar
• KLEINBERG ML, WANKE LA: New approaches and tech-nologies in drug design and discovery. Am. J. Health-Syst. Pharm. (1995) 52:1323–1336.
   PubMed Web of Science ®Google Scholar
• WURTMAN RJ, BETTIKER RL: The slowing of treatment discovery, 1965–1995. Nature Med. (1995) 1 (1 0 :1122–1125.
   Google Scholar
• PERSSON CGA: In vivo veritas: the continuing impor-tance of discoveries in complex biosystems. Thorax (1996) 51:441-443. Jian Luo
   Google Scholar